Amylyx Pharmaceuticals, Inc. filed a current report on Form 8-K on August 20, 2026, disclosing that it entered into an underwriting agreement on August 19, 2026, for a public offering of 14,090,000 shares of common stock at $35.50 per share, with expected net proceeds of approximately $471.7 million.

Key Highlights

  • Offering size: 14,090,000 shares of common stock priced at $35.50 per share.
  • Net proceeds: Approximately $471.7 million after underwriting discounts, commissions, and estimated offering expenses.
  • Overallotment option: Underwriters received a 30-day option to purchase up to 2,113,500 additional shares; if exercised in full, net proceeds would increase to approximately $542.5 million.
  • Expected closing: The offering is expected to close on August 21, 2026, subject to customary closing conditions.
  • Stated use of proceeds: The company disclosed it intends to use proceeds to fund the potential commercial launch of avexitide in the United States, if approved, including securing additional manufacturing capacity, and for research and development, working capital, and other general corporate purposes.
  • Lead underwriters: Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC served as representatives of the underwriters.

Amylyx Discloses Underwriting Agreement Terms and Intended Use of Offering Proceeds

According to the filing, Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) entered into an underwriting agreement on August 19, 2026, with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC as representatives of the several underwriters. The agreement covers the issuance and sale of 14,090,000 shares of common stock, par value $0.0001 per share, at a public offering price of $35.50 per share. All shares in the offering are being sold by the company.

The company reported that aggregate net proceeds, after deducting underwriting discounts, commissions, and other estimated offering expenses, are expected to be approximately $471.7 million. If the underwriters exercise their 30-day overallotment option to purchase up to 2,113,500 additional shares in full, net proceeds would reach approximately $542.5 million, according to the filing. The offering is being made pursuant to a prospectus supplement dated August 19, 2026, and an accompanying base prospectus forming part of a registration statement on Form S-3ASR (File No. 333-293956), which the filing states became automatically effective upon filing with the SEC on March 3, 2026.

The filing states that Amylyx intends to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund the potential commercial launch of avexitide in the United States if approved, including securing additional manufacturing capacity to meet commercial supply requirements, and for research and development, working capital, and other general corporate purposes. The company noted that statements regarding completion of the offering, anticipated closing, expected proceeds, and use of proceeds are forward-looking statements subject to risks and uncertainties, and that "no assurance can be given that the Offering discussed above will be completed."

What Was Disclosed

Amylyx Pharmaceuticals disclosed the entry into an underwriting agreement for a public offering of 14,090,000 shares at $35.50 per share, with expected net proceeds of approximately $471.7 million, intended primarily to support the potential commercial launch of avexitide, if approved.